skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

We’re excited to share our latest report on gene, cell, and rna therapies with The American Society of Gene and Cell Therapy (ASGCT). This Q4 2022 report calls out important updates and changes within the gene, cell, and rna therapy landscape.

Highlights of the report include:

Across 2022, the pipeline (preclinical to pre-registration) of gene, cell, and RNA therapies has grown by 7%

  • The gene therapy pipeline itself grew by 6%, and 2022 saw five gene therapies approved for the first time, two of which are indicated for hemophilia. Oncology and rare diseases remain the most commonly targeted indications by gene therapies both across the pipeline and in the clinic
  • The RNA pipeline grew the most throughout 2022, increasing by 17%

Q4 2022 specifically saw three new approvals

  • Two new gene therapy approvals in the US: etranacogene dezaparvovec (Hemgenix) for hemophilia B, and nadofaragene firadenovec (Adstiladrin) for bladder cancer
  • A cell therapy, tabelecleucel (Ebvallo), was also approved for Epstein-Barr virus-positive post-transplant lymphoproliferative disease in the EU

Dealmaking and financing by advanced molecular companies was down in Q4

  • The total number of deals signed by advanced molecular companies saw a decrease of 27% in the final quarter of 2022 compared with Q3; one bright spot, however, was a large uptick in acquisitions, which have doubled in the last year
  • Start-up financing also declined in Q4, with only 10 companies raising Series A or seed rounds, for an aggregate $310.3 million
  • Top fundraiser iECURE, an in vivo gene editing company, brought in $65 million from Novo 

About Citeline Custom Intelligence


When you work with our Custom Intelligence team you gain access to the deep subject matter expertise of a global network of over 400 pharma and medtech industry experts, underpinned by the market-leading data of the Citeline product suite.

Your project lead will work in collaboration with you to understand your requirements, assign dedicated consultant support, and arrange analyst research to deliver actionable solutions in accordance with your business goals. 

Whether you lack available staff, want an objective perspective, or need outside expertise, our team assesses your needs and provides in-depth research, expert insights, and innovative strategies that lead to success.

Report Contributors

Practice Lead

Ly Nguyen-Jatkoe, PhD

Executive Director, Pharma Custom Intelligence

Ly Specialises in

  • Competitive Intelligence
  • Business Development and Licensing
  • Product Launch and Commercial Strategy

22+ years of experience


Amanda Micklus

Senior Pharma Consultant

Connecticut , USA

Amanda Micklus_Pharma_Intelligence

Amanda Specialises in

  • Business Development and Licensing
  • Market intelligence
  • Primary market research

23+ years of experience


Shardha Millington

Consultant, Pharma Custom Intelligence
Shardha Millington

Shardha Specialises in

  • Market intelligence
  • Drug development
  • Research and Development
  • Competitive Intelligence

Previous Reports

Thank you for requesting a demo

We have received your request and we will get back to you soon.

Privacy Policy    Terms of Use

By continuing, you accept Pharma Intelligence UK may contact you with updates, relevant promotions and information about products provided by Pharma Intelligence UK. You understand that your information will be used in accordance with our Privacy Policy, and that you may withdraw your permission to receive any of our communications at any time.

You can unsubscribe at any time by following the links in any emails we send to you or by emailing See our Privacy Policy.